Differential gene methylation patterns in cancerous and non ‑cancerous cells.
Differential gene methylation patterns in cancerous and non‑cancerous cells. Oncol Rep. 2019 May 15;: Authors: Kamińska K, Białkowska A, Kowalewski J, Huang S, Lewandowska MA Abstract Large‑scale projects, such as The Cancer Genome Atlas (TCGA), Human Epigenome Project (HEP) and Human Epigenome Atlas (HEA), provide an insight into DNA methylation and histone modification markers. Changes in the epigenome significantly contribute to the initiation and progression of cancer. The goal of the present study was to characterize the prostate cancer malignant transformation model using the CpG island methylation pattern. The Human Prostate Cancer EpiTect Methyl II Signature PCR Array was used to evaluate the methylation status of 22 genes in prostate cancer cell lines: PC3, PC3M, PC3MPro4 and PC3MLN4, each representing different metastatic potential in vivo. Subsequently, it was ascertained whether DNA methylation plays a role in the expression of these genes in prostate cancer cells. Hypermethylation of APC, DKK3, GPX3, GSTP1, MGMT, PTGS2, RASSF1, TIMP2 and TNFRSF10D resulted in downregulation of their expression in prostate cancer cell lines as compared to WT fibroblasts. Mining of the TCGA data deposited in the MetHC database found increases in the methylation status of these 9 genes in prostate cancer patients, further supporting the role of methylation in altering the expression of these genes in prostate cancer. Future studies are warranted to investi...
Condition: Prostate Adenocarcinoma Intervention: Combination Product: MVA-BN-Brachyury Sponsors: University of Utah; Bavarian Nordic; Genentech, Inc. Not yet recruiting
Conditions: Prostate Cancer; Recurrent Prostate Cancer Intervention: Drug: Nivolumab Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Bristol-Myers Squibb Not yet recruiting
Conditions: Prostate Cancer; Prostate Adenocarcinoma; Prostate Neoplasm; Prostate Cancer Metastatic; Castration-resistant Prostate Cancer Interventions: Drug: Talazoparib; Drug: Temozolomide Sponsor: Memorial Sloan Kettering Cancer Center Recruiting
VANCOUVER and HOUSTON, July 15, 2019 -- (Healthcare Sales &Marketing Network) - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatmen... Biopharmaceuticals, Oncology, Personnel ESSA Pharma, prostate cancer, aniten
ConclusionsIpatasertib, at the monotherapy MTD of 600 mg/day and MAD of 400 mg/day in combination with abiraterone and prednisolone, was safe and tolerable in Japanese patients with solid tumors.
ConclusionPCC alone is not enough to improve a cancer survivor ’s confidence in their ability to manage their health in the presence of multiple chronic conditions.Implications for Cancer SurvivorsCancer survivors with multiple chronic conditions need ongoing support, in addition to PCC, that render them prepared to manage their health after cancer.
ConclusionHigh-resolution micro-ultrasound identified clinically significant cancer that would have, otherwise, been missed by both MRI fusion and systematic biopsy and was useful in both biopsy na ïve and repeat negative patients. Early results from this small, single-center cohort are promising, particularly given the ease with which micro-ultrasound can replace the conventional ultrasound in standard prostate biopsy procedures.
ConclusionOur findings suggest that PA during AS for PCa does not significantly influence time to curative treatment.
In this study, we found the AgNPs effectively induces cytotoxicity, ROS and apoptosis by modulation of intrinsic apoptoic Bcl2, Bclxl, Bax and Caspase 3 protein expressions in LNCap cell lines. Based on the study, synthesis of AgNPs from S. miltiorrhiza shows eco-friendly and it exhibits antimicrobial and anticarcinogenic effects. PMID: 31299869 [PubMed - in process]